|
(V70) |
Impact of gender on 1-year outcomes after implantation of bioresorbable drug-eluting scaffolds |
|
|
M. Baquet, D. Gjermeni, M. Bajraktari, D. Jochheim, D. Dischl, D. Sibbing, G. Tarantini, S. Massberg, J. Mehilli (München; Padua, IT) |
|
|
Diskussion |
|
(V71) |
Two-year results of patients undergoing everolimus-eluting bioresorbable scaffold implantation in daily routine – results from the ISAR-ABSORB Registry |
|
|
J. Wiebe, P. Hoppmann, Y. Harada, S. Kufner, S. Cassese, J. Bohner, R. Colleran, E. Xhepa, T. Ibrahim, S. Schneider, H. Schunkert, K.-L. Laugwitz, A. Kastrati, R. Byrne (München) |
|
|
Diskussion |
|
(V72) |
A matched comparison of everolimus-eluting and novolimus-eluting bioresorbable scaffolds in a real-world scenario |
|
|
J. Wiebe, H. Ilstad, O. Dörr, O. Husser, C. Liebetrau, N. F. Boeder, T. Bauer, H. Möllmann, A. Kastrati, C. W. Hamm, H. Nef (München, Gießen, Bad Nauheim, Dortmund) |
|
|
Diskussion |
|
(V73) |
Vascular response to biodegradable polymer sirolimus-eluting and permanent polymer everolimus-eluting stents — a randomized optical coherence tomography study |
|
|
T. Koppara, T. Tada, E. Xhepa, T. Ibrahim, K.-L. Laugwitz, C. Hengstenberg, H. Schunkert, A. Kastrati, M. Joner, R. Waksman (München; Washington, DC, US) |
|
|
Diskussion |
|
(V74) |
Drug eluting stents in clinical routine: A 1-year follow-up analysis based on health insurance administrative data |
|
|
M. Möckel, J. Searle, C. Günster, H. T. Baberg, P. Dirschedl, B. Levenson, J. Malzahn, T. Mansky, E. Jeschke (Berlin, Lahr/Baden) |
|
|
Diskussion |
|
(V75) |
Early versus delayed invasive strategies in patients with non-ST-elevation acute coronary syndrome: A collaborative individual patient data-based meta-analysis of randomized trials |
|
|
A. Jobs, S. Desch, H. Thiele (Lübeck) |
|
|
Diskussion |